Last updated: February 27, 2026
What Is the Product?
NDC 66758-0149 corresponds to Tazverik (tazemetostat), an oral EZH2 inhibitor approved by the FDA in July 2020. It is indicated for treatment of epithelioid sarcoma and certain lymphomas, including follicular lymphoma in specific cases.
Market Landscape
Oncology Treatment Market Overview
The global oncology market was valued at approximately USD 174 billion in 2022, with targeted therapies accounting for a growing segment due to recent approvals and innovation. Tazemetostat targets a niche within epigenetic therapy, gaining typical interest from patients with rare cancers like epithelioid sarcoma and follicular lymphoma.
Sales Performance and Revenue Trends
- 2019-2022: The product received accelerated approval and launched in late 2020. Sales in the U.S. reached USD 120 million in 2022, with growth driven by expanding indications and increased physician adoption.
- Key Drivers: Rare cancer indication, FDA approval, orphan drug status, and high unmet need.
Competition and Market Share
Primary competitors include other epigenetic modifiers and targeted agents such as:
| Drug |
Indication |
Approval Year |
Market Share (2022) |
Brand Name |
| Tazverik (tazemetostat) |
Epithelioid sarcoma, follicular lymphoma |
2020 (FDA) |
40% |
Tazverik |
| Vyxeos (CPX-351) |
AML |
2017 |
25% |
Vyxeos |
| Beyfortus (quarfloxacine) |
Lymphoma |
Under review |
10% |
N/A |
Note: Market shares are estimates based on sales and prescription data.
Price Projections
Current Pricing Framework
- Wholesale Acquisition Cost (WAC): Approximately USD 19,300 per month per patient (average wholesale price, AWP).
- Per Treatment Course: Estimated at USD 231,600 over 12 months for a standard dosage.
- Patient Access: Insurance reimbursement, specialty pharmacy pricing adjustments influence out-of-pocket costs.
Near-term Price Trends (Next 2 Years)
- Annual price increases are limited by pricing pressures in the U.S. healthcare market, expected to average 3-5%.
- Launch of expanded indications and potential biosimilars (if developed) may pressure prices downward.
- Specialty pharmacy and payer negotiations likely will reduce net prices, with discounts estimated at 10-15%.
Long-term Projections (3-5 Years)
- With increased adoption, prices are expected to stabilize or decrease slightly, especially if new competitors enter the niche.
- Based on historical trends in oncology drugs, net pricing could see a 2-4% annual decline post-market saturation.
- Incorporation of value-based pricing strategies and rebate adjustments will influence actual transaction prices.
Pricing and Revenue Outlook Table
| Year |
Estimated WAC (USD/year) |
Estimated Market Penetration |
Projected Revenue (USD millions) |
| 2023 |
19,300/month (~ USD 231,600/year) |
25% of eligible patients |
USD 150 million |
| 2024 |
20,000/month (~ USD 240,000/year) |
30% |
USD 180 million |
| 2025 |
20,500/month (~ USD 246,000/year) |
35% |
USD 210 million |
Note: These figures assume 10,000 eligible patients annually, with regional variation in adoption rates.
Future Market Expectations
- Growth driven by new indications, especially in combination therapies.
- Entry into European and Asian markets may influence global pricing strategies.
- Competitive pressures from biosimilars or generic epigenetic agents could lead to significant price reductions after patent expiration (~2030).
Key Takeaways
- NDC 66758-0149 (Tazverik) is a targeted epigenetic therapy with a niche but growing market.
- Sales are projected to grow between 15-20% annually through 2025, driven by expanding indications and increased prescribing.
- Current U.S. list prices hover around USD 19,300 per month, with expected modest increases in the short term.
- Pricing pressures and competition will likely temper increases and could drive prices lower over the next 3-5 years.
- The limited patent life and potential biosimilar emergence are critical factors for long-term revenue.
Frequently Asked Questions
1. How does Tazverik's price compare to other targeted oncology therapies?
It is generally aligned with other specialized epigenetic and targeted therapies, which often range from USD 15,000 to USD 25,000 per month.
2. What factors could significantly alter future price projections?
Market entry of biosimilars, new indications increasing patient base, or changes in regulatory policies affecting drug pricing.
3. How does regulatory status affect pricing?
FDA approvals and orphan drug designations enable premium pricing during exclusivity periods but can also lead to downward pressure when exclusivity expires.
4. What is the average patient treatment duration for Tazverik?
Typically 12 months, but duration depends on response and tolerability, with some patients continuing treatment longer.
5. Are international markets likely to adopt Tazverik at similar prices?
Prices vary significantly due to regional healthcare policies, with European prices generally lower due to negotiations and government controls.
References
- U.S. Food and Drug Administration. (2020). FDA approves first targeted treatment for epithelioid sarcoma. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-treatment-epithelioid-sarcoma
- IQVIA. (2022). Oncology Market Data.
- EvaluatePharma. (2023). World Oncology Drug Market Data.
- CMS. (2022). Medicare Part B Drug Pricing and Reimbursement Data.
- IQVIA Institute. (2023). The Future of Oncology: The Growing Impact of Targeted Therapies.
[Note: Data sources include FDA filings, IQVIA reports, and market surveys from 2022-2023 are used for projections.]
